Copyright
©The Author(s) 2020.
World J Gastroenterol. Jun 28, 2020; 26(24): 3447-3457
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3447
Published online Jun 28, 2020. doi: 10.3748/wjg.v26.i24.3447
Table 1 Patient characteristics
Table 2 TAIM staging system
Severity | Location | ||
Antrum | Corpus | Whole stomach | |
No atrophy/IM | Low (0) | Low (0) | Low (0) |
Mild atrophy/IM | Low (I) | Low (I) | Low (I) |
Moderate atrophy/IM | Low (II) | Low (II) | High (II-III) |
Marked atrophy/IM | High (III) | High (II) | High (IV) |
Table 3 Operative link for gastritis assessment staging
Corpus | ||||
0 (No atrophy) | 1 (Mild) | 2 (Moderate) | 3 (Marked) | |
Antrum 0 (No atrophy) | 0 (1/103) | I (3/116) | II (7/395) | II (8/259) |
Antrum 1 (Mild) | I (0/5) | I (0/15) | II (3/60) | III (0/26) |
Antrum 2 (Moderate) | II (0/4) | II (0/6) | III (1/32) | IV (1/26) |
Antrum 3 (Marked) | III (0/0) | III (0/7) | IV (2/41) | IV (2/42) |
Table 4 Operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings and gastric cancer risk
n | Gastric cancers | H. pylori pos (%) | HR | 95%CI | P value | |
OLGA stage | ||||||
0 | 103 | 1 | 25.2 | 1.00 | ||
I | 136 | 3 | 44.1 | 2.66 | 0.28-25.72 | |
II | 724 | 18 | 24.7 | 2.84 | 0.38-21.38 | 0.10 |
III | 65 | 1 | 35.4 | 1.85 | 0.11-29.87 | |
IV | 109 | 5 | 25.7 | 5.77 | 0.67-49.77 | |
OLGIM stage | ||||||
0 | 205 | 2 | 33.7 | 1.00 | ||
I | 404 | 7 | 28.0 | 1.82 | 0.37-8.83 | |
II | 316 | 10 | 27.8 | 3.55 | 0.77-16.36 | 0.004 |
III | 115 | 5 | 26.1 | 5.91 | 1.14-30.73 | |
IV | 100 | 4 | 18.0 | 5.72 | 1.03-31.77 | |
TAIM stage | ||||||
Low | 475 | 6 | 32.6 | 1.00 | ||
High | 662 | 22 | 24.3 | 2.70 | 1.09-6.69 | 0.03 |
Table 5 Operative link on gastric intestinal metaplasia assessment staging
Corpus | ||||
0 (No IM) | 1 (Mild) | 2 (Moderate) | 3 (Marked) | |
Antrum 0 (No IM) | 0 (2/205) | I (2/239) | II (5/133) | II (2/31) |
Antrum 1 (Mild) | I (2/45) | I (3/120) | II (1/88) | III (1/39) |
Antrum 2 (Moderate) | II (0/15) | II (2/49) | III (2/45) | IV (1/32) |
Antrum 3 (Marked) | III (1/14) | III (1/17) | IV (2/30) | IV (1/38) |
Table 6 TAIM staging
Severity | Location | ||
Antrum | Corpus | Whole stomach | |
No atrophy/IM | 0 | 0 | 1/74 |
Mild atrophy /IM | 0/14 | 1/87 | 0/35 |
Moderate atrophy /IM | 0/5 | 4/260 | 8/235 |
Marked atrophy /IM | 0 | 5/179 | 9/248 |
Table 7 Gastric cancer cases during the follow-up period by operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings
Cases/Men | % | Sensitivity (%) | Specificity (%) | |
OLGA | ||||
0-II | 22/963 | 2.28 | 21.4 | 84.9 |
III-IV | 6/174 | 3.45 | ||
OLGIM | ||||
0-II | 19/925 | 2.05 | 32.1 | 81.4 |
III-IV | 9/215 | 4.19 | ||
TAIM | ||||
low | 6/475 | 1.26 | 78.6 | 42.3 |
high | 22/662 | 3.32 |
Table 8 Standardized incidence rates of general male population compared to low and high-risk patients in operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM staging systems
SIR | 95%CI | P value | |
OLGA | |||
General population | 1.00 | ||
Low (0-II) | 2.10 | 1.32-3.18 | 0.003 |
High (III-IV) | 3.03 | 1.11-6.60 | 0.03 |
OLGIM | |||
General population | 1.00 | ||
Low (0-II) | 1.86 | 1.12-2.90 | 0.02 |
High (III-IV) | 4.00 | 1.83-7.60 | 0.001 |
TAIM | |||
General population | 1.00 | ||
Low-risk | 1.17 | 0.43-2.54 | 0.82 |
High-risk | 3.00 | 1.88-4.55 | < 0.001 |
- Citation: Nieminen AA, Kontto J, Puolakkainen P, Virtamo J, Kokkola A. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis. World J Gastroenterol 2020; 26(24): 3447-3457
- URL: https://www.wjgnet.com/1007-9327/full/v26/i24/3447.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i24.3447